{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"8.950","floor":"8.180"},"ipodate":{"start":"2020-03-11 00:00:00","end":"2020-03-16 00:00:00"},"minimumcapital":"9040.19","subscribed":"298.75","marketcap":"112.02億","H_marketcap":"--","pe":"--","codesrate":"25.00","link":"https://staticpdf.iqdii.com/stockdata/notice/09969/2020/2020031100036_c.pdf","ipopricing":"8.950","resultdate":"2020-03-20 00:00:00","enddate":"2020-03-16 00:00:00","listeddate":"2020-03-23 00:00:00","issuenumber":"25032.40萬","issuenumberhK":"12516.20萬","issuenumberother":"12516.20萬","grayprice":"10.22","sponsors":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司","raisemoney":"209308.00萬","use":"1、預期約1,046.54百萬港元（相當于所得款項凈額的50.0%）將用作為奧布替尼同時在中國及美國正在進行和計劃進行的臨床試驗、準備注冊文件及潛在的商業推出（包括銷售和營銷）提供資金；\n2、預期約523.27百萬港元（相當于所得款項凈額的25.0%）將用作為我們的兩個臨床階段候選產品提供資金；\n3、預期約313.96百百萬港元（相當于所得款項凈額的15.0%）將用作為我們管線中的六種IND準備階段的候選藥物的研發以及新候選藥物的研發及外部引進提供資金；\n4、預期約209.31百萬港元（相當于所得款項凈額的10.0%）將用作我們的營運資金及其他一般企業用途。","shares":1000,"leadagent":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,瑞士銀行香港分行,招商證券(香港)有限公司,招銀國際融資有限公司,浦銀國際融資有限公司","bookrunners":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,瑞士銀行香港分行,招商證券(香港)有限公司,招銀國際融資有限公司,浦銀國際融資有限公司","coordinator":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,瑞士銀行香港分行,招商證券(香港)有限公司","firstDayOpen":"9.40","IsEiio":0,"Interestdays":4,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E09969","name":"諾誠健華－Ｂ","fullname":"諾誠健華醫藥有限公司"},"institutioninfo":{"principaloffice":"中國北京市昌平區中關村生命科學園生命園路8號院8號樓","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"崔霽松","secretary":"王承鏱","telephone":"(8610) 6660 9999","substantialshareholders":"Hebert Pang Kee Chan(12.89%),趙仁濱博士及家族成員(12.43%),崔霽松博士及家族成員(11.38%),LVC實體(9.66%),Vivo Capital(6.8%)","principalactivities":"公司是一家處于臨床階段的生物醫藥公司,致力于發現、研發及商業化潛在同類最佳及/或首創的用于治療癌癥及自身免疫性疾病的藥物。","website":"http://www.innocarepharma.com"},"managerinfo":[{"managername":"崔霽松","post":"主席、執行董事兼行政總裁","rankno":1},{"managername":"趙仁濱","post":"執行董事","rankno":2},{"managername":"施一公","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"中國國有企業結構調整基金股份有限公司","shareholding":"26,711,000.0","percentage":10.67,"ReleaseDate":"2020-09-23 00:00:00","relatedparty":"國務院國資委","subsidiary":["中國誠通控股集團有限公司","中國國有企業結構調整基金股份有限公司","中國機械工業集團有限公司","中國商用飛機有限責任公司","中國西電集團公司"],"InverstorType":"公司"},{"institutionname":"Vivo Funds","shareholding":"19,080,000.0","percentage":7.62,"ReleaseDate":"2020-09-23 00:00:00","relatedparty":"Vivo Capital LLC","subsidiary":["Vivo Funds"],"InverstorType":"基金"},{"institutionname":"Matthews Asia Funds","shareholding":"17,554,000.0","percentage":7.01,"ReleaseDate":"2020-09-23 00:00:00","relatedparty":"Matthews International Capital Management, LLC","subsidiary":["Matthews Asia Funds","銘基基金"],"InverstorType":"基金"},{"institutionname":"Tiger Pacific Master Fund LP","shareholding":"11,448,000.0","percentage":4.57,"ReleaseDate":"2020-09-23 00:00:00","relatedparty":"Tiger Pacific Capital LP","subsidiary":["Tiger Pacific Master Fund LP"],"InverstorType":"基金"}],"TotalShareholdingPercentage":49.99},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":12}